Literature DB >> 26405781

Screening for colorectal cancer in Italy: 2011-2012 survey.

Manuel Zorzi1, Filippo Da Re, Paola Mantellini, Carlo Naldoni, Priscilla Sassoli De'Bianchi, Carlo Senore, Anna Turrin, Carmen Beatriz Visioli, Marco Zappa.   

Abstract

We present the main results of the 2011-2012 survey of the Italian screening programmes for colorectal cancer carried out by the National centre for screening monitoring (Osservatorio nazionale screening, ONS) on behalf of the Ministry of Health. By the end of 2012, 112 programmes were active, of which 11 had been activated during 2012 and 4 during 2011. The national theoretical extension increased from 66% of Italians aged 50-69 years residing in areas covered by organized screening programmes in 2010 to 73.7% in 2012. The majority of programmes employ the fecal immunochemical test (FIT), while some have adopted flexible sigmoidoscopy (FS) once in a lifetime and FIT for non-responders to FS. Overall, about 7,744,000 subjects were invited to undergo FIT, 53.1% of those to be invited within the two years. The adjusted attendance rate was 47.1%and 3,531,937 subjects were screened. Large differences in the attendance rate were observed among regions. Positivity rate of FIT programmes was 5.2% at first screening (range: 1.0-12.4%) and 4.0% at repeat screening (range: 3.4-6.4%). The average attendance rate to total colonoscopy (TC) was 81.2% and in two regions (Molise and Campania) it was lower than 70%. Completion rate for total colonoscopy (TC) was 91%. Among the 1,316,327 subjects attending screening for the first time, the detection rate (DR) per 1,000 screened subjects was 2.0 for invasive cancer and 9.1 ‰ for advanced adenomas (AA, adenomas with a diameter ≥1 cm, with villous/tubulo-villous type or high-grade dysplasia). As expected, the corresponding figures in the 2,215,610 subjects at repeat screening were lower (1.0‰ and 6.8‰ for invasive cancer and AA, respectively). Many programmes reported some difficulties in guaranteeing TC in the appropriate time frame to FIT+ subjects: in 15% of cases the waiting time was longer than two months. Ten programmes in 2011 and eight in 2012 employed FS as the screening test: 24,549 subjects were screened in the two years, with an attendance rate of 24.5%. Overall, 85.9% of FSs were classified as complete. Overall, TC referral rate was 9.8% and the DR per 1,000 screened subjects was 3.0 and 48.2 for invasive cancer and AA, respectively.

Entities:  

Mesh:

Year:  2015        PMID: 26405781

Source DB:  PubMed          Journal:  Epidemiol Prev        ISSN: 1120-9763            Impact factor:   1.901


  6 in total

1.  Predictors of colorectal cancer screening awareness among people working in a hospital environment.

Authors:  Spyridon Michopoulos; Efstathios Manios; Helias Kourkoutas; Konstantinos Argyriou; Georgios Leonidakis; Evanthia Zampeli; Kimon Stamatelopoulos; Athanasios-Meletios Dimopoulos
Journal:  Ann Gastroenterol       Date:  2017-02-09

2.  The impact of COVID-19 pandemic in the colorectal cancer prevention.

Authors:  Giovanna Del Vecchio Blanco; Emma Calabrese; Livia Biancone; Giovanni Monteleone; Omero Alessandro Paoluzi
Journal:  Int J Colorectal Dis       Date:  2020-06-04       Impact factor: 2.571

3.  Assessing emotions conveyed and elicited by patient narratives and their impact on intention to participate in colorectal cancer screening: A psychophysiological investigation.

Authors:  Teresa Gavaruzzi; Michela Sarlo; Francesca Giandomenico; Rino Rumiati; Francesca Polato; Franca De Lazzari; Lorella Lotto
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

4.  Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer.

Authors:  Giovanna Del Vecchio Blanco; Rami Dwairi; Mario Giannelli; Giampiero Palmieri; Vincenzo Formica; Ilaria Portarena; Enrico Grasso; Laura Di Iorio; Michela Benassi; Emilia Anna Giudice; Antonella Nardecchia; Piero Rossi; Mario Roselli; Giuseppe Sica; Giovanni Monteleone; Omero Alessandro Paoluzi
Journal:  Intern Emerg Med       Date:  2021-02-08       Impact factor: 3.397

5.  Colorectal cancer screening by fecal immunochemical test or colonoscopy in France: how many people are actually covered? Focus on the Provence-Alpes-Côte d'Azur region.

Authors:  Jean-François Seitz; David Lapalus; Sylvie Arlotto; Stéphanie Gentile; Florence Ettori; Yves Rinaldi; Philippe Grandval; Patrick Delasalle
Journal:  Eur J Gastroenterol Hepatol       Date:  2022-04-01       Impact factor: 2.566

6.  Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer.

Authors:  Manuel Zorzi; Jessica Battagello; Kevin Selby; Giulia Capodaglio; Susanna Baracco; Silvia Rizzato; Enrico Chinellato; Stefano Guzzinati; Massimo Rugge
Journal:  Gut       Date:  2021-03-31       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.